This is the third point I want to address as part of my effort to explore the capacity constraints in the German healthcare system. Part one was looking at cost of care and part two from yesterday was about the origins of the physicians shortages in Germany. 200 years ago
To continue the cost of care thread from yesterday, the second big capacity constraint is around clinicians. Here is a quick recipe for how to think about this problem: 1. First we take specialists such as radiologists and dermatologists (in-patient care) vs GPs (out-patient care). 2. Second we
Last week I listed what I believe are the main factors contributing to capacity constraints in the healthcare system in Germany. Some of those are being already addressed in various ways, while others remain an open field (or shall we call it a blue ocean?): * Reimbursement incentives: Until recently, hospitals
There are three main problems with the healthcare system in Germany: 1. Bad economics: cost of care is too high. This is driven by many factors, including reimbursement incentives, high manual work, various system inefficiencies and silos, and the medical field simply developing further and finding ever more cures for
From a16z: To understand where AI fits, it helps to decompose drug discovery into its three essential stages: 1.Disease-to-mechanism: Identifying a biological mechanism — a pathway, a target, a molecular interaction — where therapeutic intervention will alter the course of disease in humans. 2.Mechanism-to-drug: Creating a
There is a lot to be said and seen about how the KHVVG and KHZG reforms are going to change the German healthcare market, but the goals are clear, from Springer Nature: The financing reform, as a central component of the Hospital Care Improvement Act (KHVVG), was associated with a
AI is a change agent and NfX suggests three ways how the workflow might change: The first idea is that specialised AI tools - for example for diagnosis, documentation or billing - will need to be managed and orchestrated into a single smooth workflow. The opportunity is in owning and orchestrating the
From Fierce Biotech: GSK is boosting its AI chops with a new deal worth up to $110 million with Relation. The British Big Pharma and AI-focused biotech will work together in a new research collaboration focused on “generating large-scale human cellular perturbation data and deploying them into models,
Yesterday Apotheke Adhoc reported that dm-med, dm’s entry into the online pharmacy market, is not yet disrupting other online pharmacies (translated): In terms of product range, dm-med remains significantly more limited compared to traditional mail-order pharmacies. According to an analysis, the drugstore chain's subsidiary
From kma Online (translated, emphasis mine): Grim prospects: Germany is already short approximately 4,400 general practitioners. By 2040, this gap could widen to around 12,000 unfilled GP positions – that would be roughly one in five positions nationwide. This is shown in the recently published study "Primary Care
In Clinician Economics, Part 1 I briefly covered the concept of unit economics and entertained the idea of applying that to a clinical setting in the context of new products entering the market. In Part 2 I illustrated why the in-patient clinician may not be particularly inclined to adopt
In Clinician Economics, Part 1 I briefly wrote about the idea of unit economics and tried to setup the stage for how that may be applied in a healthcare setting, starting with two distinct types of clinicians - the in-patient and out-patient physician. Now let’s see how those